SLL
Approved in relapsed
SLL after 2 systemic
therapies

ZYDELIG®
Patient Profile

Consider ZYDELIG for patients with relapsed SLL
after 2 prior therapies

Patient With Prior BR Treatment and BR Retreatment
relapsed small lymphocytic lymphomas (SLL) patient relapsed small lymphocytic lymphomas (SLL) patient

Profile and photo are representative of patients in clinical trials but are not actual cases. For illustrative purposes only.

History

History

  • 70-year-old male
  • Takes metformin for type 2 diabetes

Diagnosis

Diagnosis

2009, SLL

Presentation

  • Ann Arbor stage IV
  • Normal blood counts
  • Multiple enlarged nodes
  • ECOG performance status of 2

Prior
therapies

Prior therapies

At development of B symptoms

  • BR
  • BR retreatment

Current presentation

Current presentation

B symptoms have recurred

  • Across clinical trials, ZYDELIG had similar efficacy in patients aged ≥65 years and in younger patients
    • Older patients had a higher incidence of discontinuation due to AEs, serious AEs, and death

AE=adverse event; BR=bendamustine, rituximab; ECOG=Eastern Cooperative Oncology Group; SLL=small lymphocytic lymphoma.